INT52962

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.47
First Reported 1995
Last Reported 2011
Negated 3
Speculated 2
Reported most in Body
Documents 77
Total Number 79
Disease Relevance 50.03
Pain Relevance 1.49

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (ERBB2) signal transduction (ERBB2) plasma membrane (ERBB2)
nucleus (ERBB2) cytoplasm (ERBB2)
Anatomy Link Frequency
arm 3
2C4 2
cerebrospinal fluid 2
liver 1
colon 1
ERBB2 (Homo sapiens)
Pain Link Frequency Relevance Heat
tolerance 24 93.40 High High
Inflammation 362 92.76 High High
Pain 48 90.28 High High
headache 40 84.60 Quite High
antagonist 27 80.04 Quite High
methotrexate 8 77.24 Quite High
agonist 11 76.08 Quite High
alcohol 13 74.16 Quite High
abdominal pain 9 71.28 Quite High
cva 33 65.20 Quite High
Disease Link Frequency Relevance Heat
Breast Cancer 2265 100.00 Very High Very High Very High
Advanced Or Metastatic Breast Cancer 909 100.00 Very High Very High Very High
Nicotine Addiction 2 100.00 Very High Very High Very High
Cancer 2742 99.84 Very High Very High Very High
Inflammatory Breast Neoplasms 423 99.84 Very High Very High Very High
Ovarian Cancer 149 99.76 Very High Very High Very High
Aneuploidy 11 99.74 Very High Very High Very High
Exanthema 278 99.72 Very High Very High Very High
Noninfiltrating Intraductal Carcinoma 34 99.66 Very High Very High Very High
Disease 1009 99.28 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Approximately 20%–25% of breast cancers overexpress human epidermal receptor type 2 (ErbB2 or HER2), which is associated with a more aggressive cancer and predicts poor clinical outcome (Slamon et al 1987).
HER2 Binding (associated) of associated with cancer and breast cancer
1) Confidence 0.47 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727787 Disease Relevance 0.93 Pain Relevance 0
Approximately 20%–25% of breast cancers overexpress human epidermal receptor type 2 (ErbB2 or HER2), which is associated with a more aggressive cancer and predicts poor clinical outcome (Slamon et al 1987).
ErbB2 Binding (associated) of associated with cancer and breast cancer
2) Confidence 0.47 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727787 Disease Relevance 0.93 Pain Relevance 0
We analyzed COX-2 expression in human breast cancers (and breast cancer cell lines) and adjacent ductal carcinoma in situ (DCIS) as well as its association with HER2/neu and clinicopathological variables.
neu Spec (analyzed) Binding (association) of associated with breast cancer and noninfiltrating intraductal carcinoma
3) Confidence 0.47 Published 2002 Journal Cancer Res. Section Abstract Doc Link 11912139 Disease Relevance 1.05 Pain Relevance 0
Simultaneous inhibition of the ErbB2 receptor by trastuzumab, which binds the extracellular domain of ErbB2, and lapatinib, which binds the intracellular kinase, showed superiority over lapatinib therapy alone.10,23 In a phase III trial, patients (n = 296) receiving the combination had significantly improved progression-free survival (PFS) (12.0 weeks for the combination vs 8.4 weeks for lapatinib monotherapy; HR 0.77; 95% CI 0.6 to 1.0; P = 0.029) and clinical benefit rate (CBR) (25.2 vs 13.2%; P = 0.020).23 There was no observed difference for overall survival (OS).
ErbB2 Binding (binds) of
4) Confidence 0.45 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004582 Disease Relevance 0.20 Pain Relevance 0.03
Simultaneous inhibition of the ErbB2 receptor by trastuzumab, which binds the extracellular domain of ErbB2, and lapatinib, which binds the intracellular kinase, showed superiority over lapatinib therapy alone.10,23 In a phase III trial, patients (n = 296) receiving the combination had significantly improved progression-free survival (PFS) (12.0 weeks for the combination vs 8.4 weeks for lapatinib monotherapy; HR 0.77; 95% CI 0.6 to 1.0; P = 0.029) and clinical benefit rate (CBR) (25.2 vs 13.2%; P = 0.020).23 There was no observed difference for overall survival (OS).
ErbB2 Binding (binds) of
5) Confidence 0.45 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004582 Disease Relevance 0.19 Pain Relevance 0.03
As described, a powerful interaction between Her2 and EGFR exists.
Her2 Binding (interaction) of
6) Confidence 0.44 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721347 Disease Relevance 0.64 Pain Relevance 0
In contrast, for other 17q amplicons (17q21.32, 17q21.32-q22, 17q23.1q23.2 and 17q23.3) we did not found any association with ERBB2-amplified tumors; (v) the two amplified subregions within 19q12 amplifications (with frequencies of 12% and 16%, respectively) coud be associated exclusively with the basal subtype.
ERBB2 Binding (association) of associated with cancer
7) Confidence 0.44 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958950 Disease Relevance 0.29 Pain Relevance 0
The HercepTest (DAKO) is directed against the intracellular region of ERBB2 with high sensitivity; TAB250 anti-ERBB2 recognizes with high specificity but low sensitivity the extracellular region of the receptor [10].
ERBB2 Binding (recognizes) of
8) Confidence 0.44 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958950 Disease Relevance 0.05 Pain Relevance 0.04
As pertuzumab inhibits heterodimerization of HER1/HER2, this rash was considered as possibly related to treatment.
HER2 Neg (inhibits) Binding (heterodimerization) of associated with exanthema
9) Confidence 0.42 Published 2009 Journal Japanese Journal of Clinical Oncology Section Body Doc Link PMC2661001 Disease Relevance 1.33 Pain Relevance 0.07
We analyzed COX-2 expression in human breast cancers (and breast cancer cell lines) and adjacent ductal carcinoma in situ (DCIS) as well as its association with HER2/neu and clinicopathological variables.
HER2 Spec (analyzed) Binding (association) of associated with breast cancer and noninfiltrating intraductal carcinoma
10) Confidence 0.42 Published 2002 Journal Cancer Res. Section Abstract Doc Link 11912139 Disease Relevance 1.05 Pain Relevance 0
Molecular interactions between HER2 and other members of its family (HER1 or EGFR, HER3 and HER4) have led to the development of new targeted therapies such as the anti-EGFR monoclonal antibody cetuximab, the anti-EGFR oral small molecule tyrosine kinase inhibitors erlotinib and gefitinib, and the dual EGFR-HER2 tyrosine kinase inhibitor lapatinib [96].
HER2 Binding (interactions) of
11) Confidence 0.37 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 0.56 Pain Relevance 0
Pertuzumab inhibits the formation of the HER2 heterodimer, independent of HER2 expression levels, and its binding site does not overlap with the epitope on HER2 that is recognized by trastuzumab (Herceptin) (14,15).
HER2 Binding (recognized) of
12) Confidence 0.37 Published 2009 Journal Japanese Journal of Clinical Oncology Section Body Doc Link PMC2661001 Disease Relevance 1.07 Pain Relevance 0.17
Lapatinib plus capecitabine for ErbB2-positive advanced breast cancer
ErbB2 Binding (capecitabine) of associated with advanced or metastatic breast cancer
13) Confidence 0.37 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727787 Disease Relevance 0.49 Pain Relevance 0
Like most human IBC samples, MARY-X is ER-negative, progesterone receptor-negative, p53-positive, and epidermal growth factor receptor-positive, but is Her-2/neu-negative.
Her-2/neu Binding (negative) of associated with inflammatory breast neoplasms
14) Confidence 0.36 Published 2005 Journal Breast Cancer Res Section Body Doc Link PMC1064141 Disease Relevance 1.44 Pain Relevance 0.11
Like most human IBC samples, MARY-X is ER-negative, progesterone receptor-negative, p53-positive, and epidermal growth factor receptor-positive, but is Her-2/neu-negative.
Her-2/neu Binding (negative) of associated with inflammatory breast neoplasms
15) Confidence 0.36 Published 2005 Journal Breast Cancer Res Section Body Doc Link PMC1064141 Disease Relevance 1.38 Pain Relevance 0.11
Monoclonal antibody 4D5, which recognizes the extracellular domain of the HER2/neu receptor, was administered into the cerebrospinal fluid of athymic rats implanted with human breast cancer cell lines.
HER2/neu Binding (recognizes) of in cerebrospinal fluid associated with breast cancer
16) Confidence 0.36 Published 2001 Journal Clin. Cancer Res. Section Abstract Doc Link 11448923 Disease Relevance 0.36 Pain Relevance 0.12
Monoclonal antibody 4D5, which recognizes the extracellular domain of the HER2/neu receptor, was administered into the cerebrospinal fluid of athymic rats implanted with human breast cancer cell lines.
HER2/neu Binding (recognizes) of in cerebrospinal fluid associated with breast cancer
17) Confidence 0.36 Published 2001 Journal Clin. Cancer Res. Section Abstract Doc Link 11448923 Disease Relevance 0.36 Pain Relevance 0.12
Trastuzumab (Herceptin, Genentech, Inc., South San Francisco, California) is a highly purified recombinant DNA-derived humanized monoclonal immunoglobulin G1 kappa antibody that binds with high affinity and specificity to the extracellular domain of the HER2 receptor.
HER2 receptor Binding (binds) of
18) Confidence 0.36 Published 1999 Journal Clin Ther Section Abstract Doc Link 10211534 Disease Relevance 0.33 Pain Relevance 0
The association of HER2 with a specific type suggests that intestinal- and diffuse-type gastric cancers develop along different molecular pathways and supports earlier studies showing distinct patterns of genetic alterations in gastric cancers of differing histopathologic features [85].
HER2 Binding (association) of associated with stomach cancer
19) Confidence 0.36 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 1.45 Pain Relevance 0
Subsequently, dimerization of activated EGFR with other HER family receptors, particularly HER2, activates intracellular signaling pathways, which in turn may enhance nuclear ER signaling [4], thus completing a vicious cycle of events.
HER2 Binding (dimerization) of
20) Confidence 0.35 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001220 Disease Relevance 0.30 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox